By Bruce Buckley
Efforts to advance the use of preemptive pharmacogenetic (PGx) testing to help clinicians predict patients’ response to high-risk specialty and other medications are hitting some snags in the managed care sector.
Some health insurers are reluctant to reimburse for the multigene panel tests required to optimize clinical decision making, according to a new study by investigators from St. Jude Children’s Research Hospital and the University of Mississippi School of